BioGaia (SE)
BioGaia AB is a Swedish healthcare company engaged in the development and commercialization of probiotic products. The company operates primarily through two business segments: Pediatrics and Adults. Its product portfolio is based on proprietary strains of Limosilactobacillus reuteri bacteria, packaged as drops, chewable tablets, capsules, and lozenges. Primary revenue drivers are product sales of finished probiotic supplements alongside component supply and royalty fees from distribution partners. BioGaia holds a leading global market position in pediatric probiotic drops and gut health solutions. The company is headquartered in Stockholm, Sweden, and its shares are listed on Nasdaq Stockholm.
32 of the funds FundTelligence covers report a position in BioGaia (SE).
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 32
Funds holding BioGaia (SE)
- TIN Ny Teknik — Tin Fonder · 6.39 % (full portfolio disclosed, June 2026)
- Case Gaia Microcap — Case · 4.4 % (full portfolio disclosed, June 2026)
- Nordea Innovation Sustainable Stars — Nordea Funds · 3.98 % (full portfolio disclosed, June 2026)
- Case All Star Småbolag — Case · 3.31 % (full portfolio disclosed, June 2026)
- Schroder ISF Nordic Smaller Companies — Schroders · 2.78 % (full portfolio disclosed, June 2026)
- Aktiespararna Småbolag Edge — Cicero Fonder · 2.74 % (full portfolio disclosed, June 2026)
- Simplicity Småbolag Sverige — Simplicity · 2.31 % (full portfolio disclosed, June 2026)
- Pareto Småbolagsfond — Pareto · 1.82 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 32 funds holding it.